Kappa-opioid receptors differentially regulate low and high levels of ethanol intake in female mice.
Studies in laboratory animals and humans indicate that endogenous opioids play an important role in regulating the rewarding value of various drugs, including ethanol (EtOH). Indeed, opioid antagonists are currently a front-line treatment for alcoholism in humans. Although roles for mu- and delta-opioid receptors have been characterized, the contribution of kappa-opioid receptors (KORs) is less clear. There is evidence that changes in KOR system function can decrease or increase EtOH drinking, depending on test conditions. For example, female mice lacking preprodynorphin - the precursor to the endogenous KOR ligand dynorphin - have reduced EtOH intake. Considering that KORs can regulate dopamine (DA) transmission, we hypothesized that KORs expressed on DA neurons would play a prominent role in EtOH intake in females.



We used a Cre/loxPrecombination strategy to ablate KORs throughout the body or specifically on dopamine uptake transporter (DAT)-expressing neurons to investigate the role of KORs on preference for and intake of EtOH (2-bottle choice), the transition from moderate to excessive EtOH drinking (intermittent EtOH access), and binge EtOH drinking (drinking in the dark [DID]).



KOR deletion decreased preference for EtOH, although this effect was less pronounced when EtOH intake increased beyond relatively low levels.



Our findings indicate that KOR activation increases EtOH drinking via effects mediated, at least in part, by KORs on DA neurons. While the mechanisms of this regulation remain unknown, previous work suggests that alterations in negative reinforcement processes or sensitivity to the sensory properties of EtOH can affect preference and intake.
Department of Psychiatry Harvard Medical School McLean Hospital Belmont MA USA; National Institute of Neurological Disorders and Stroke National Institutes of Health Bethesda MD USA.
Ashlee
A
Van't Veer
Department of Psychiatry Harvard Medical School McLean Hospital Belmont MA USA.
Karen L
KL
Smith
Department of Psychiatry Harvard Medical School McLean Hospital Belmont MA USA.
Bruce M
BM
Cohen
Department of Psychiatry Harvard Medical School McLean Hospital Belmont MA USA.
William A
WA
Carlezon
Department of Psychiatry Harvard Medical School McLean Hospital Belmont MA USA; National Institute on Alcohol Abuse and Alcoholism National Institutes of Health Bethesda MD USA.
Anita J
AJ
Bechtholt
drinking; ethanol; kappa
Psychopharmacology (Berl). 1998 Sep;139(1-2):62-70
9768543
Pharmacol Biochem Behav. 1990 Feb;35(2):385-90
2320646
Psychopharmacology (Berl). 2000 Sep;151(4):321-7
11026738
Alcohol Clin Exp Res. 1993 Jun;17(3):631-6
8392818
Neuropsychopharmacology. 2000 May;22(5):493-503
10731624
Brain Res. 1996 May 20;721(1-2):126-31
8793092
Neuropsychopharmacology. 1996 Feb;14(2):139-49
8822536
Behav Brain Res. 2014 Oct 1;272:238-47
25026094
Biol Psychol. 2011 Sep;88(1):51-6
21736916
Alcohol Clin Exp Res. 2002 Sep;26(9):1381-7
12351933
Alcohol Clin Exp Res. 2005 May;29(5):730-8
15897716
J Pharmacol Exp Ther. 1993 Sep;266(3):1236-46
7690399
Alcohol Clin Exp Res. 2015 Sep;39(9):1712-26
26331879
Brain Res. 2010 Feb 16;1314:44-55
19716811
Alcohol Clin Exp Res. 2001 Nov;25(11):1634-47
11707638
Psychopharmacologia. 1973;29(3):203-10
4702273
Alcohol. 1986 Jan-Feb;3(1):39-54
3964437
Neuropsychopharmacology. 2013 Jul;38(8):1585-97
23446450
Alcohol Clin Exp Res. 2010 Feb;34(2):214-22
19951300
Alcohol Clin Exp Res. 2011 Apr;35(4):652-8
21223302
Alcohol. 1984 Jan-Feb;1(1):33-7
6543609
Annu Rev Psychol. 1989;40:191-225
2648975
Pharmacol Biochem Behav. 1998 Mar;59(3):627-35
9512064
Neuropsychopharmacology. 1998 Mar;18(3):135-74
9471114
Alcohol Alcohol. 2000 Nov-Dec;35(6):587-93
11093966
Psychopharmacology (Berl). 2005 Nov;182(3):384-92
16001119
Physiol Behav. 2005 Jan 31;84(1):53-63
15642607
Behav Neurosci. 2005 Feb;119(1):213-23
15727526
J Med Chem. 2013 Mar 28;56(6):2178-95
23360448
Neuropharmacology. 2006 Sep;51(3):487-96
16781738
Brain Res. 1988 Oct 11;462(1):126-33
3179728
Pharmacol Biochem Behav. 2004 Apr;77(4):783-92
15099924
Eur J Neurosci. 2006 Aug;24(3):885-93
16930416
Neuropsychopharmacology. 2014 Jan;39(2):254-62
24121188
Psychopharmacology (Berl). 2013 Oct;229(3):435-52
23836029
Brain Behav. 2016 Jul 24;6(9):e00523
27688945
J Clin Psychopharmacol. 2002 Dec;22(6):592-8
12454559
Addict Biol. 2013 May;18(3):496-507
22862671
J Neurosci. 1999 Oct 1;19(19):RC29
10493774
Am J Geriatr Psychiatry. 1997 Fall;5(4):324-32
9363289
Alcohol. 2006 Oct;40(2):73-86
17307643
Psychopharmacology (Berl). 2004 Apr;172(4):463-70
14727002
Arch Gen Psychiatry. 1992 Nov;49(11):876-80
1345133
Alcohol Alcohol Suppl. 1987;1:333-7
3426696
J Pharmacol Exp Ther. 1988 Mar;244(3):1067-80
2855239
Alcohol. 2000 Jul;21(3):215-21
11091024
Int J Neuropsychopharmacol. 2013 Jun;16(5):975-85
23101464
Biol Psychiatry. 2013 May 1;73(9):819-26
23044182
N Engl J Med. 2001 Dec 13;345(24):1734-9
11742047
Ann N Y Acad Sci. 1992 Jun 28;654:171-91
1632582
Med J Aust. 2002 Jun 3;176(11):530-4
12064984
Behav Brain Res. 2002 Aug 21;134(1-2):123-30
12191798
Biol Psychiatry. 2014 May 15;75(10):774-82
23611261
J Clin Psychopharmacol. 2001 Jun;21(3):287-92
11386491
Pharmacol Biochem Behav. 1985 Jan;22(1):91-9
3975250
Behav Brain Res. 2001 May;120(2):137-46
11182162
Pharmacol Biochem Behav. 1983 Dec;19(6):1045-8
6657723
Addict Biol. 2011 Jan;16(1):116-9
20579007
Science. 1982 Jan 22;215(4531):413-5
6120570
Psychopharmacology (Berl). 1999 Mar;142(3):309-17
10208324
Alcohol Clin Exp Res. 1997 Jun;21(4):691-702
9194926
Mol Psychiatry. 2006 Nov;11(11):1016-24
16924269
Arch Gen Psychiatry. 1992 Nov;49(11):881-7
1444726
Alcohol Clin Exp Res. 1999 Sep;23(9):1468-76
10512312
Am J Psychiatry. 1999 Nov;156(11):1758-64
10553740
J Pharmacol Exp Ther. 2003 Jan;304(1):310-8
12490606
Behav Pharmacol. 2001 Sep;12(5):325-33
11710747
Psychol Rev. 1987 Oct;94(4):469-92
3317472
Recent Dev Alcohol. 1992;10:201-33
1350359